Nefense, a leader in advanced clinical hygiene and airway health solutions, has officially launched its hypochlorous acid (HOCl) nasal spray line, marking a significant advancement in age-specific respiratory defense. The new product portfolio, which includes formulations for adults, children, and infants, aims to address the growing need for safe and effective nasal care amid rising concerns over respiratory infections and seasonal allergies.
The flagship product, Hyponasal spray, delivers a gentle yet clinical-grade biocleanse that flushes out airborne irritants, provides immediate soothing relief, and supports the body's natural respiratory defenses. According to the company, the spray leverages the broad-spectrum antimicrobial and anti-inflammatory properties of hypochlorous acid, a substance naturally produced by the immune system, to neutralize bacteria and viruses, help prevent upper respiratory infections, and combat seasonal allergies without the use of harsh chemicals or steroids.
This launch comes as consumers increasingly seek alternatives to traditional nasal sprays that often contain steroids or decongestants, which can have side effects or lead to dependency. Nefense's HOCl-based approach offers a non-irritating, pH-balanced solution that is safe for regular use across all age groups. The company emphasizes that the formulations were developed in collaboration with doctors and ENT specialists to ensure efficacy and safety.
Nefense's product expansion underscores a broader trend toward proactive airway hygiene. By offering age-specific options, the company aims to address the unique anatomical and physiological needs of different age groups. For infants, the spray is designed to be extra gentle, while formulations for children and adults provide varying concentrations and delivery mechanisms to optimize comfort and effectiveness.
Many clinics and practices nationwide now offer the Nefense nasal spray family, including XyloClean, a xylitol-based nasal spray that helps moisturize and rebalance nasal passages. The company's growing portfolio reflects its commitment to bridging the gap between daily hygiene, airway health, restorative sleep, and overall wellness.
The implications of this announcement are significant for public health. Upper respiratory infections and allergies affect millions annually, and the availability of a gentle, non-pharmaceutical option could reduce reliance on antibiotics and steroids. Moreover, the age-specific approach allows for tailored prevention strategies from infancy through adulthood, potentially lowering the incidence of chronic sinus issues and improving quality of life.
For more information, the full announcement is available here.
